Skip to content

Exercise and Respiratory Training as Supportive Treatments for Patients With Chronic Pulmonary Hypertension

Phase 3 Study of Physical Exercise and Respiratory Training as Supportive Treatments for Patients With Severe Chronic Pulmonary Hypertension

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01398345
Enrollment
30
Registered
2011-07-20
Start date
2003-04-30
Completion date
Unknown
Last updated
2014-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pulmonary Hypertension

Brief summary

Background -Pulmonary hypertension (PH) is associated with restricted physical capacity, limited quality of life, and a poor prognosis because of right heart failure. The present study is the first prospective randomized study to evaluate the effects of exercise and respiratory training in patients with severe symptomatic PH. Methods -Patients with PH on stable disease-targeted medication will be randomly assigned to a control and a primary training group. Medication will remain unchanged during the study period. Primary end points will be the changes from baseline to week 15 in the distance walked in 6 minutes and in scores of the Short Form Health Survey quality-of-life questionnaire. Changes in WHO functional class, Borg scale, and parameters of echocardiography and gas exchange also will be assessed. Prospects -We hope this study will indicate that respiratory and physical training are a promising adjunct to medical treatment in severe PH.

Interventions

BEHAVIORALExercise and Respiratory Training

Patients in the interventional group will participate in an exercise program 7 days a week at low workloads (10 to 60 W) that will be supervised by physical therapists and physicians.

Sponsors

Heidelberg University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Patients with severe chronic PH who were stable and compensated under optimized medical therapy (such as endothelin antagonists, iloprost, sildenafil, calcium channel blockers, anticoagulants, diuretics, and supplemental oxygen) for at least 3 months before entering the study will be invited to participate. Additional inclusion criteria will be age of between 18 and 75 years and World Health Organization (WHO) functional class II to IV.

Exclusion criteria

* Patients with recent syncope or skeletal or muscle abnormalities prohibiting participation in an exercise program won't be included.

Design outcomes

Primary

MeasureTime frame
distance walked in 6 minutesbaseline - 15 weeks afterwards
change in quality of life as measured by the Short Form Health Survey (SF-36) questionnairebaseline - 15 weeks afterwards

Secondary

MeasureTime frame
changes in WHO functional classificationbaseline - 15 weeks afterwards
Borg scale assessed immediately after completion of the stress Doppler echocardiographybaseline - 15 weeks afterwards
parameters of echocardiographybaseline - 15 weeks afterwards
parameters of gas exchangebaseline - 15 weeks afterwards

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026